November 2, 2015

VIA EDGAR TRANSMISSION

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-6010

 

Attention:

Suzanne Hayes, Assistant Director

Alla Berenshteyn

 

Re:	Kura Oncology, Inc.

Registration Statement on Form S-1 (Registration No. 333-207534)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “1933 Act”), the undersigned, Citigroup Global Markets Inc. and Leerink Partners LLC, as the representatives of the underwriters (the “Representatives”) of the offering pursuant to the above-captioned Registration Statement on Form S-1 (the “Registration Statement”), hereby join the Company in requesting that the effective date for the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on November 4, 2015, or as soon thereafter as possible, pursuant to Rule 430A.

In connection with this acceleration request and pursuant to Rule 460 under the 1933 Act, we wish to advise you that we have effected the following distribution of the preliminary prospectus included in the Registration Statement dated October 28, 2015:

Preliminary Prospectus: approximately 794 copies to prospective underwriters, dealers, institutions and others.

The several underwriters are aware of their obligations under and confirm that they are complying with the provisions of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, including the delivery requirement contained in such Rule.

[Signature Page Follows]

---

[Signature Page to Acceleration Request]